**Name of Journal:** *World Journal of Radiology*

**Manuscript NO:** 55725

**Manuscript Type:** MINIREVIEWS

**Lung cancer screening, what has changed after the latest evidence?**

Trujillo-Reyes JC *et al*. LC screening, latest evidence

Juan Carlos Trujillo-Reyes, Luis Seijo, Elisabeth Martínez-Tellez, Felipe Couñago

**Juan Carlos Trujillo-Reyes, Elisabeth Martinez-Tellez**, Department of Thoracic Surgery, Hospital de la Santa Creu I Sant Pau, Barcelona 08029, Spain

**Juan Carlos Trujillo-Reyes, Elisabeth Martinez-Tellez**, Department of surgery, Universitat Autonoma de Barcelona, Barcelona 08029, Spain

**Luis Seijo**, Department of Pneumology, Clinica Universitaria de Navarra, Madrid 28029, Spain

**Felipe Couñago**,Department of Radiation Oncology, Hospital Universitario Quirónsalud Madrid, Madrid 28223, Spain

**Felipe Couñago**, Universidad Europea de Madrid, Madrid 28223,Spain

**Author contributions:** Trujillo-Reyes JC was involved in the study conceptualization, investigation, data visualization and writing of the original draft; Seijo L performed formal analysis, review and editing of the manuscript; Martinez-Tellez E was involved in the investigation, data visualization and review and editing of the manuscript; Couñago F participated in the investigation, data validation and writing, review and editing of the manuscript; All authors have read and approved the final manuscript.

**Corresponding author: Juan Carlos Trujillo-Reyes, MD, Adjunct Professor, Surgical Oncologist**, Department of Thoracic Surgery, Hospital Universitari de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona 08029, Spain. jtrujillo@santpau.cat

**Received:** March 30, 2020

**Revised:** June 11, 2020

**Accepted:** July 1, 2020

**Published online:** July 28, 2020

**Abstract**

Lung cancer (LC) is still one of the most frequent cancers with a high related mortality. Their prognosis is directly proportional to the stage at the time of diagnosis. Seventy percent are currently diagnosed in advanced or locally advanced stage (higher than stage III), making a cure unlikely for the majority of patients. Developments in LC treatment are significant however they do not seem to be enough to reverse the current situation, at least, in a short period of time. Despite recent advances in treatment, primary prevention and early diagnosis appear to be the key to reduce the incidence and mortality of this disease. Many countries have developed LC screening programs based on the results of clinical trials published in recent years. The aim of this paper is to review the latest results of the NEderlands Leuvens Longkanker Screenings Onderzoek and compare them with the findings of the National Lung Screening Trial. We address the question whether it is necessary to continue discussing the evidence regarding LC screening. In both trials, there is a clear impact on LC mortality but, with a modest reduction in over all mortality. Undoubtedly, the benefit of screening can be expected to grow as low-dose computed tomographys are performed over longer periods of time.

**Key words:** Lung cancer; Epidemiology; Lung cancer screening; Low dose chest computed tomography scan; Primary prevention; Molecular biomarkers

**Citation:** Trujillo-Reyes JC, Seijo L, Martinez-Tellez E, Couñago F. Lung cancer screening, what has changed after the latest evidence? *World J Radiol* 2020; 12(7): 130-136

**URL:** https://www.wjgnet.com/1949-8470/full/v12/i7/130.htm

**DOI:** https://dx.doi.org/10.4329/wjr.v12.i7.130

**Core tip:** In recent years, many publications have focused on primary prevention and Lung cancer (LC) screening. Currently, most scientific societies recommend some form of LC screening. However, implementation around the world has been slow, at least in part because of a continued controversy regarding some aspects of LC screening. The aim of this article is to analyze the recently published results of the NEderlands Leuvens Longkanker Screenings Onderzoek study and compare them to those of the American National Lung Screening Trial (NLST). There is a clear impact on LC mortality in both trials, but only the NLST revealed a reduction in overall mortality (7%).

**INTRODUCTION**

Lung cancer (LC) is the most lethal of all cancers. It is the leading cause of death from cancer worldwide and, year after year, the number of new LC cases grows[1].

One of the most important prognostic factors is the stage at the time of diagnosis. Most patients are asymptomatic until they develop an advanced stage making an early diagnosis challenging[2].

Despite important advance in oncological treatments, the prevalence and persistently elevated mortality associated with lung cancer demand a paradigm shift. Primary prevention initiatives must continue, but for many current and former smokers early recognition of pulmonary nodules must be pursued. Many countries have developed laws related to primary prevention that have proven insufficient to stem the tide of lung cancer. The combination of primary prevention and LC screening could help us fight the disease before it is too late.

LC screening has become a reality in the United States following completion of the National Lung Screening Trial (NLST)[3] . The cultural gap existing between the United States and Europe and the difference between both health systems created some skepticism in the European community regarding the potential benefit of lung cancer screening programs in our continent. Results of the NEderlands Leuvens Longkanker Screenings Onderzoek (NELSON)[4] study may assuage those concerns and provide a much needed impulse for efforts regarding the implementation of LC screening in Europe. Both trials investigated the role of low dose CT as the screening tool of choice[5-8].

**LUNG CANCER EPIDEMIOLOGY**

The figures show how the global number of LC cases is increasing demonstrating that LC is the leading cause of cancer-related mortality worldwide. In 2015[9], approximately 1.6 million new LC cases were diagnosed worldwide and, according to the World Health Organization, more than 2 million new cases were diagnosed in 2019 alone, and LC was responsible for the cancer 1.76 million deaths.

That notwithstanding, LC death rates declined 48% from 1990 to 2016 among men and 23% from 2002 to 2016 among women. The American Association for Cancer Research published in 2018 that lung cancer mortality rates among women are [projected to increase](https://www.curetoday.com/articles/women-face-increased-global-mortality-in-lung-cancer-declines-in-breast-cancer-by-2030) by about 43 percent between 2015 to 2030.

This high mortality is related to the fact that 70% of cases are diagnosed in an advanced stage (stage III or IV disease)[10] being the 5 year-survival a 16% for stage III and 4% for stage IV[11].

***Risk factors***

Smoking continues being as the major etiological factor[11], althoughoccupational exposure to carcinogens such asbestos and radon[12,13], family history of LC[14], genetic predisposition and other concomitant diseases may also play a role.

**Tobacco use**: It is the major etiological factor. We can prevent almost 200 million people from dying before 2050 halving tobacco consumption[11], but smoking in many countries continues to increase. In Spain, for example, the number of smokers is the same in 2017 as in 1997 despite implementation of two anti-smoking laws is even greater among the youth. Unfortunately, it is not an isolated example. It is crucial to prevent smoking in adolescence because, the patients who started smoking within this age group, have four or five-fold increased risk of developing a LC[15]. It is well known that passive smokers have a higher risk for LC when compared to nonsmokers. However, the association is too weak to be considered in a LC screening program[16].

**Occupational exposure:** The association between LC and approximately 150 carcinogens is well known being asbestos, crystalline silica or radon[17] a few examples. It is important to note that the combination of smoking and to be exposed to these carcinogens further increases the risk of developing LC. Air pollution may also play an important role in the development of LC in urban populations.

**Pre-existing lung illnesses:** (1) Chronic obstructive pulmonary disease (COPD), Emphysema, Bronchitis: COPD and emphysema are associated with an increased LC risk[18-20]. This association may be caused by tobacco-use, however, this association is evidence in never-smokers too[21,22]; and (2) Idiophatic pulmonary fibrosis: patients who develop interstitial fibrosis also have a higher risk to develop a LC[23,24].

**Genetic predisposition:** A systematic review of the literature performed by Matakidou *et al*[25] showed an increased risk of LC in patients with a first-degree relative with LC. A genetic locus that may be associated with a greatest risk of developing LC has been described[26].

Identifying the presence of these risk factors could be crucial to define the population at risk and inform LC screening inclusion criteria.

**LUNG CANCER SCREENING**

The main objective of LC screening is to detect the greatest number of people in early stage when symptoms have not yet appeared and treatment with curative intent may be possible[16]. It is important to consider that a LC screening program must take into account quality of life and life expectancy. Key elements of a successful screening program are defined in Table 1.

In lung cancer screening, several questions must be addressed before implementation, but these are not easy questions to answer: What population should be screened? Is it safe and economically viable? What is the age of the population to be screened? What is the periodicity of the screening? What is the best screening tool?

In recent years several publications have attempted to address at least some of these concerns, and to provide the needed evidence to demonstrate the feasibility and efficacy of a LC screening program. Most of them used low-dose computed tomography (LDCT) as the main screening tool, however, only two randomized trials have been published using the LDCT test, NLST and recently published, NELSON trial.

**NLST AND NELSON STUDIES**

***NLST, the North American evidence***

The NLST was the first large prospective randomized trial investigating the benefit of LC screening. The aim of the NLST was to determine whether screening with LDCT could reduce mortality form LC and more than 50000 individuals at risk for LC were randomized to undergo three rounds of screening with LDCT or chest radiography. Inclusion criteria were restrictive including patients between 55 and 74 years old with a high smoking habit (≥ 30 pack/year).

The results of the NLST showed a reduction of more than 20% in LC mortality and 40% of LC detected were in early stage of the disease. False positive results were common demonstrating a Positive Predictive Value lower than 4% for LDCT. Part of the success was the high adherence from the study participants[3].

Overdiagnosis was a major source of controversy surrounding the NLST, although a recent publication with long term follow up suggests that true overdiagnosis is approximately 3%.

***NELSON, the European evidence***

The NELSON trial is the largest randomized trial of LC screening, which the European health systems needed to adapt to our idiosyncrasies and population. Although, the sample size was smaller (less than 16000 participants) than the NLST’s, the results confirm the reduction in lung cancer mortality[4]. Inclusion criteria and intervals were flexible reducing the rate of false positives (postive predictive value 43.5%).

The impact of both trials highlights the reduction in LC mortality with no differences in overall survival compared to the control group. Table 2 shows details of both trials.

**HOW TO IMPROVE LC SCREENING?**

We are aware that LDCT screening requires compromises, and no screening program is ideal. Improvement in selection criteria and nodule management may come from molecular biomarkers[27] and multiple potential candidates have been identified and studied in the context of LC screening[28,29]. Autoantibodies, complement fragments, miRNAs, circulating tumour DNA, DNA methylation, blood protein profiling, or RNA airway or nasal signatures are all promising molecular candidates. Seijo et al. defined the two clinical needs of biomarkers; the selection of individuals undergoing screening and the characterization of indeterminate nodules[27].

The strategy has to be focused on the addition of molecular biomarkers to current screening practices.

**CONCLUSION**

LC remains a health crisis worldwide with an increasing financial impact[30]. It is now apparent that a combination of primary prevention and LC screening may be the key to reducing the incidence of this disease and its attendant mortality. The NLST[3] has paved the way for LC screening in the United States, where it is now standard of care for those meeting the study’s inclusion criteria. In Europe, a lack of evidence has been alluded to in order to delay implementation of screening. However, results of the NELSON study are now available and published confirming the benefit of LC screening for individulas at risk[4].

In our opinion, both the NELSON and the NLST have provided sufficient scientific evidence to warrant widespread screening. Of course, both randomized trials can be criticized and we can continue discussing advantages and disadvantages of LC screening but, in our opinion, they confirm that LC screening is feasible and has a clear benefit on the population.

There is a clear impact on LC mortality but, in both trials, with a modest reduction in over all mortality. Undoubtedly, the benefit of screening can be expected to grow as LDCTs are performed over longer periods of time[31].

LDCT is currently the test of choice. Addition of molecular biomarkers may offer a more selective approach in the future.

**ACKNOWLEDGEMENTS**

We would like to express our gratitude to Jose Antonio Trujillo-Reyes for his contribution and to the rest of Thoracic Surgery, Radiotherapy and Pulmonology for allowing us to continue enjoying with our job.

**REFERENCES**

1 **Thun MJ**, Henley SJ, Burns D, Jemal A, Shanks TG, Calle EE. Lung cancer death rates in lifelong nonsmokers. *J Natl Cancer Inst* 2006; **98**: 691-699 [PMID: 16705123 DOI: 10.1093/jnci/djj187]

2 **Tylski E**, Goyal M. Low Dose CT for Lung Cancer Screening: The Background, the Guidelines, and a Tailored Approach to Patient Care. *Mo Med* 2019; **116**: 414-419 [PMID: 31645796]

3 **National Lung Screening Trial Research Team.**, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med* 2011; **365**: 395-409 [PMID: 21714641 DOI: 10.1056/NEJMoa1102873]

4 **de Koning HJ**, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, Lammers JJ, Weenink C, Yousaf-Khan U, Horeweg N, van 't Westeinde S, Prokop M, Mali WP, Mohamed Hoesein FAA, van Ooijen PMA, Aerts JGJV, den Bakker MA, Thunnissen E, Verschakelen J, Vliegenthart R, Walter JE, Ten Haaf K, Groen HJM, Oudkerk M. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. *N Engl J Med* 2020; **382**: 503-513 [PMID: 31995683 DOI: 10.1056/NEJMoa1911793]

5 **Saghir Z**, Dirksen A, Ashraf H, Bach KS, Brodersen J, Clementsen PF, Døssing M, Hansen H, Kofoed KF, Larsen KR, Mortensen J, Rasmussen JF, Seersholm N, Skov BG, Thorsen H, Tønnesen P, Pedersen JH. CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT. *Thorax* 2012; **67**: 296-301 [PMID: 22286927 DOI: 10.1136/thoraxjnl-2011-200736]

6 **Pastorino U**, Rossi M, Rosato V, Marchianò A, Sverzellati N, Morosi C, Fabbri A, Galeone C, Negri E, Sozzi G, Pelosi G, La Vecchia C. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. *Eur J Cancer Prev* 2012; **21**: 308-315 [PMID: 22465911 DOI: 10.1097/CEJ.0b013e328351e1b6]

7 **Infante M**, Cavuto S, Lutman FR, Passera E, Chiarenza M, Chiesa G, Brambilla G, Angeli E, Aranzulla G, Chiti A, Scorsetti M, Navarria P, Cavina R, Ciccarelli M, Roncalli M, Destro A, Bottoni E, Voulaz E, Errico V, Ferraroli G, Finocchiaro G, Toschi L, Santoro A, Alloisio M; DANTE Study Group. Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography. *Am J Respir Crit Care Med* 2015; **191**: 1166-1175 [PMID: 25760561 DOI: 10.1164/rccm.201408-1475OC]

8 **Field JK**, Duffy SW, Baldwin DR, Whynes DK, Devaraj A, Brain KE, Eisen T, Gosney J, Green BA, Holemans JA, Kavanagh T, Kerr KM, Ledson M, Lifford KJ, McRonald FE, Nair A, Page RD, Parmar MK, Rassl DM, Rintoul RC, Screaton NJ, Wald NJ, Weller D, Williamson PR, Yadegarfar G, Hansell DM. UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. *Thorax* 2016; **71**: 161-170 [PMID: 26645413 DOI: 10.1136/thoraxjnl-2015-207140]

9 **Malvezzi M**, Bertuccio P, Rosso T, Rota M, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? *Ann Oncol* 2015; **26**: 779-786 [PMID: 25623049 DOI: 10.1093/annonc/mdv001]

10 **Siegel RL**, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin* 2018; **68**: 7-30 [PMID: 29313949 DOI: 10.3322/caac.21442]

11 **Gouvinhas C**, De Mello RA, Oliveira D, Castro-Lopes JM, Castelo-Branco P, Dos Santos RS, Hespanhol V, Pozza DH. Lung cancer: a brief review of epidemiology and screening. *Future Oncol* 2018; **14**: 567-575 [PMID: 29417838 DOI: 10.2217/fon-2017-0486]

12 **Lee HA**, Lee WK, Lim D, Park SH, Baik SJ, Kong KA, Jung-Choi K, Park H. Risks of Lung Cancer due to Radon Exposure among the Regions of Korea. *J Korean Med Sci* 2015; **30**: 542-548 [PMID: 25931783 DOI: 10.3346/jkms.2015.30.5.542]

13 **SELIKOFF IJ**, CHURG J, HAMMOND EC. ASBESTOS EXPOSURE AND NEOPLASIA. *JAMA* 1964; **188**: 22-26 [PMID: 14107207 DOI: 10.1001/jama.1964.03060270028006]

14 **Jonsson S**, Thorsteinsdottir U, Gudbjartsson DF, Jonsson HH, Kristjansson K, Arnason S, Gudnason V, Isaksson HJ, Hallgrimsson J, Gulcher JR, Amundadottir LT, Kong A, Stefansson K. Familial risk of lung carcinoma in the Icelandic population. *JAMA* 2004; **292**: 2977-2983 [PMID: 15613665 DOI: 10.1001/jama.292.24.3026]

15 **Minami H**, Yoshimura M, Matsuoka H, Toshihiko S, Tsubota N. Lung cancer treated surgically in patients <50 years of age. *Chest* 2001; **120**: 32-36 [PMID: 11451812 DOI: 10.1378/chest.120.1.32]

16 **Wood DE**, Kazerooni EA, Baum SL, Eapen GA, Ettinger DS, Hou L, Jackman DM, Klippenstein D, Kumar R, Lackner RP, Leard LE, Lennes IT, Leung ANC, Makani SS, Massion PP, Mazzone P, Merritt RE, Meyers BF, Midthun DE, Pipavath S, Pratt C, Reddy C, Reid ME, Rotter AJ, Sachs PB, Schabath MB, Schiebler ML, Tong BC, Travis WD, Wei B, Yang SC, Gregory KM, Hughes M. Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2018; **16**: 412-441 [PMID: 29632061 DOI: 10.6004/jnccn.2018.0020]

17 **Lorenzo-González M**, Ruano-Ravina A, Torres-Durán M, Provencio-Pulla M, Kelsey K, Parente-Lamelas I, Vidal-García I, Leiro-Fernández V, Martínez C, Hernández J, Castro-Añón O, García-García S, Sales-Fidalgo P, Abal-Arca J, Montero-Martínez C, Pérez-Ríos M, Fernández-Villar A, Barros-Dios JM. Lung cancer risk and do-it-yourself activities. A neglected risk factor for lung cancer. *Environ Res* 2019; **179**: 108812 [PMID: 31698297 DOI: 10.1016/j.envres.2019.108812]

18 **Houghton AM**, Mouded M, Shapiro SD. Common origins of lung cancer and COPD. *Nat Med* 2008; **14**: 1023-1024 [PMID: 18841139 DOI: 10.1038/nm1008-1023]

19 **Mayne ST**, Buenconsejo J, Janerich DT. Previous lung disease and risk of lung cancer among men and women nonsmokers. *Am J Epidemiol* 1999; **149**: 13-20 [PMID: 9883789 DOI: 10.1093/oxfordjournals.aje.a009722]

20 **Denholm R**, Schüz J, Straif K, Stücker I, Jöckel KH, Brenner DR, De Matteis S, Boffetta P, Guida F, Brüske I, Wichmann HE, Landi MT, Caporaso N, Siemiatycki J, Ahrens W, Pohlabeln H, Zaridze D, Field JK, McLaughlin J, Demers P, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Dumitru RS, Bencko V, Foretova L, Janout V, Kendzia B, Peters S, Behrens T, Vermeulen R, Brüning T, Kromhout H, C Olsson A. Is previous respiratory disease a risk factor for lung cancer? *Am J Respir Crit Care Med* 2014; **190**: 549-559 [PMID: 25054566 DOI: 10.1164/rccm.201402-0338OC]

21 **Yang P**, Sun Z, Krowka MJ, Aubry MC, Bamlet WR, Wampfler JA, Thibodeau SN, Katzmann JA, Allen MS, Midthun DE, Marks RS, de Andrade M. Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. *Arch Intern Med* 2008; **168**: 1097-1103 [PMID: 18504338 DOI: 10.1001/archinte.168.10.1097]

22 **Koshiol J**, Rotunno M, Consonni D, Pesatori AC, De Matteis S, Goldstein AM, Chaturvedi AK, Wacholder S, Landi MT, Lubin JH, Caporaso NE. Chronic obstructive pulmonary disease and altered risk of lung cancer in a population-based case-control study. *PLoS One* 2009; **4**: e7380 [PMID: 19812684 DOI: 10.1371/journal.pone.0007380]

23 **Hughes JM**, Weill H. Asbestosis as a precursor of asbestos related lung cancer: results of a prospective mortality study. *Br J Ind Med* 1991; **48**: 229-233 [PMID: 2025587 DOI: 10.1136/oem.48.4.229]

24 **Khan KA**, Kennedy MP, Moore E, Crush L, Prendeville S, Maher MM, Burke L, Henry MT. Radiological characteristics, histological features and clinical outcomes of lung cancer patients with coexistent idiopathic pulmonary fibrosis. *Lung* 2015; **193**: 71-77 [PMID: 25381634 DOI: 10.1007/s00408-014-9664-8]

25 **Matakidou A**, Eisen T, Houlston RS. Systematic review of the relationship between family history and lung cancer risk. *Br J Cancer* 2005; **93**: 825-833 [PMID: 16160696 DOI: 10.1038/sj.bjc.6602769]

26 **Bailey-Wilson JE**, Amos CI, Pinney SM, Petersen GM, de Andrade M, Wiest JS, Fain P, Schwartz AG, You M, Franklin W, Klein C, Gazdar A, Rothschild H, Mandal D, Coons T, Slusser J, Lee J, Gaba C, Kupert E, Perez A, Zhou X, Zeng D, Liu Q, Zhang Q, Seminara D, Minna J, Anderson MW. A major lung cancer susceptibility locus maps to chromosome 6q23-25. *Am J Hum Genet* 2004; **75**: 460-474 [PMID: 15272417 DOI: 10.1086/423857]

27 **Seijo LM**, Peled N, Ajona D, Boeri M, Field JK, Sozzi G, Pio R, Zulueta JJ, Spira A, Massion PP, Mazzone PJ, Montuenga LM. Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges. *J Thorac Oncol* 2019; **14**: 343-357 [PMID: 30529598 DOI: 10.1016/j.jtho.2018.11.023]

28 **Mazzone PJ**, Wang XF, Lim S, Jett J, Choi H, Zhang Q, Beukemann M, Seeley M, Martino R, Rhodes P. Progress in the development of volatile exhaled breath signatures of lung cancer. *Ann Am Thorac Soc* 2015; **12**: 752-757 [PMID: 25965541 DOI: 10.1513/AnnalsATS.201411-540OC]

29 **Nakhleh MK**, Amal H, Jeries R, Broza YY, Aboud M, Gharra A, Ivgi H, Khatib S, Badarneh S, Har-Shai L, Glass-Marmor L, Lejbkowicz I, Miller A, Badarny S, Winer R, Finberg J, Cohen-Kaminsky S, Perros F, Montani D, Girerd B, Garcia G, Simonneau G, Nakhoul F, Baram S, Salim R, Hakim M, Gruber M, Ronen O, Marshak T, Doweck I, Nativ O, Bahouth Z, Shi DY, Zhang W, Hua QL, Pan YY, Tao L, Liu H, Karban A, Koifman E, Rainis T, Skapars R, Sivins A, Ancans G, Liepniece-Karele I, Kikuste I, Lasina I, Tolmanis I, Johnson D, Millstone SZ, Fulton J, Wells JW, Wilf LH, Humbert M, Leja M, Peled N, Haick H. Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules. *ACS Nano* 2017; **11**: 112-125 [PMID: 28000444 DOI: 10.1021/acsnano.6b04930]

30 **Elias F**, Bou-Orm IR, Adib SM, Gebran S, Gebran A, Ammar W. Cost of Oncology Drugs in the Middle-Eastern Country of Lebanon: An Update (2014-2016). *J Glob Oncol* 2018; **4**: 1-7 [PMID: 30241263 DOI: 10.1200/JGO.17.00179]

31 **Seijo LM**, Trujillo JC, Zulueta JJ. Screening in Lung Cancer: The Latest Evidence. *Arch Bronconeumol* 2020; **56**: 7-8 [PMID: 31204006 DOI: 10.1016/j.arbres.2019.04.019]

**Footnotes**

**Conflict-of-interest statement:** Dr. Seijo reports personal fees from Sabartech, personal fees from Esteve, personal fees from Chiesi, personal fees from Astra Zeneca, grants from Menarini, and speaking fees from Roche, outside the submitted work. Rest of authors declare no conflict of interests for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding Author's Membership in Professional Societies:** Sociedad Española de Neumología y Cirugía Torácica; Sociedad Española de Cirugía Torácica; and International Thymic Malignancie Interest Group.

**Peer-review started:** March 30, 2020

**F****irst decision:** April 26, 2020

**Article in press:** July 1, 2020

**Specialty type:** Radiology, nuclear medicine and medical imaging

**Country of origin:** Spain

**Peer-review report classification**

Grade A (Excellent): A, A

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Neninger E, Sung WW, Zhou C **S-Editor:** Liu M **L-Editor:** A **E-Editor:** Liu JH

**Table 1 Quality criteria of a screening program**

|  |
| --- |
| **Quality criteria of a screening program[16]** |
| False-positive | Should be low |
| Cost | Inexpensive |
| True negative | Should not be hurt |
| Screening test should… | Improve outcomeBe scientifically validatedBe low riskBe reproducibleBe accessibleBe cost effective |

**Table 2 Comparison between nlst and nelson**

|  | **NLST** | **NELSON** |
| --- | --- | --- |
| Age | 55-74 | 50-74 |
| Smoking habit | ≥ 30 pack/year≥ 15 years since quitting | ≥ 15 pack/year≥ 10 years since quitting |
| CT scan | Diameter-based | Volume-based |
| Sample size | 53454 | 15822 |
| Number of rounds | 3 | 4 |
| Intervals | 1 yr intervals | 0, 1, 2 and 2.5 yr |
| Adherence | 95% LDCT group | 87.6% |
| Number of cancers | 1060 (645/100000 person/year) | 5.58/1000 person/year |
| % early stage cancers | 40% stage IA | 50% stage IA |
| Positive test | 24% | 2.1% |
| PPV | 3.8% | 43.5% |
| Reduction in lung cancer mortality | 20% | Higher than 20% |
| Population | North America | Europe |

NLST: National Lung Screening Trial; NELSON: Nederlands Leuvens Longkanker Screenings Onderzoek; CT: Computed tomography; LDCT: Low-dose computed tomography; PPV: Positive predictive value.